Fundraising FoxInsignis Therapeutics
North Haven, US · Founded 2018 · Delaware corporation
Find your way into Insignis Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
163 people can intro you to Mingbao
Ask Charlee Cordle to introduce you to Mingbao Zhang
You →Charlee · together at Western Connecticut State University →Mingbao
Sign up to find every way you can get introduced to Insignis Therapeutics
- Your email: who you already know at Insignis Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Insignis Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
MZ
Mingbao ZhangPresidentMingbao Zhang holds a PhD in organic chemistry from the University of Illinois, Urbana-Champaign and an Executive MBA from the University of New Haven. He has spent over 20 years in pharmaceutical drug development at companies including Bayer and Marinus Pharmaceuticals, contributed to the development of ganaxolone (approved by the FDA in 2022 for CDKL5 deficiency disorder), and founded Insignis Therapeutics to develop an epinephrine formulation for anaphylaxis treatment.
Reported raises · per SEC filings
Form D private placements$6.5M disclosed across 2 rounds · 2023–2026
▶$6MraisedAug 2026 · 4 investors · OtherRule 506(b)
▶$6MraisedAug 2026 · 4 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Mingbao ZhangExecutive Officer, Director
- Offering amount
- $8.5M
- Amount sold
- $6M
- Minimum investment
- $1
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedJun 2023 · 1 investors · OtherRule 506(c)
▶$500KraisedJun 2023 · 1 investors · Other
Rule 506(c)Officers, directors & promoters on the filing
- Mingbao ZhangExecutive Officer
- Amount sold
- $500K
- Minimum investment
- $1
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Insignis Therapeutics raised?
- Insignis Therapeutics has disclosed $6.5M raised across 2 rounds.
- Where is Insignis Therapeutics headquartered?
- Insignis Therapeutics is headquartered in North Haven, US.